Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (9554)	6/23/2006 1:24:05 AM
From: fred hayes	Respond to of 10280

Dew: Thanks for your post. If pfe can't even pursue a merger then it certainly screws up my case. Perhaps it depends on the specific language of the provision. The more I think about the whole thing, the less confident that I know anything at all about what's going on here. Think I'll have my bedtime scotch and sleep on it. Nite all...

To: DewDiligence_on_SI who wrote (9554)	6/23/2006 1:34:54 AM
From: John Metcalf	Read Replies (1) \| Respond to of 10280

Neurocrine posted the Indiplon agreement in the 2002 10-K. The part that I read doesn't say "non-compete", which I think was an expansion of public information by a poster. It says that PFE will continue its obligations for 180 days, just as Gary Lyons said today. 13.3 Other Termination: (a) Discretionary. Upon one hundred and eighty (180) days prior notice to Neurocrine, Pfizer shall have the right at any time, without cause at Pfizer's sole discretion, to terminate this Agreement, whereupon this Agreement, together with the License Agreement, shall terminate one hundred and eighty (180) days after the date of such notice.